Virulence arsenal of Acinetobacter baumannii: mechanisms driving persistence and resistance
Archives of Microbiology · 2026-04 · 208 (4)
DOI: 10.1007/s00203-025-04668-7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Archives of Microbiology, online erschienen am 02.02.2026. Verfasst von K Ayswarya und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Biotechnology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Udupi, Karnatak…. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Acinetobacter Infections, Drug Resistance, Multiple, Bacterial, Virulence Factors. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 182 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Manipal Academy of Higher Education, Manipal.
Abstract (Originalsprache)
Acinetobacter baumannii is a Gram-negative opportunistic pathogen and a major cause of healthcare-associated infections, including ventilator-associated pneumonia, bacteraemia, meningitis, and urinary tract infections. Its persistence in hospital environments is due to its ability to survive desiccation, resist disinfectants, and colonize both biotic and abiotic surfaces. Virulence in A. baumannii is largely associated with structures such as Csu pili, biofilm-associated protein (Bap), and outer membrane protein A (OmpA), which enable surface attachment, biofilm formation, and host cell damage. The production of extracellular polysaccharides and quorum sensing further enhance biofilm development. Iron uptake systems support bacterial growth even under iron-limited conditions within the host. Resistance to polymyxins often results from lipid A modifications regulated by the PmrCAB operon and LpxL -related genes, which also reduce immune recognition via the TLR4 pathway. Phase variation allows phenotypic changes that aid immune evasion. The highly adaptable genome of A. baumannii enables rapid acquisition of multiple resistance determinants, including OXA-type carbapenemases, efflux pumps, and aminoglycoside-modifying enzymes. Due to its extensive multidrug resistance, the World Health Organization lists A. baumannii as a critical-priority pathogen. This review aims to comprehensively examine the molecular mechanisms driving its virulence and resistance, highlighting potential therapeutic targets and strategies to combat this formidable pathogen.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Biotechnology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Udupi, Karnataka, 576104, India.
- Department of Pharmaceutical Chemistry, Devaki Amma Memorial College of Pharmacy, Malappuram, Chelembra, 673636, India.
- Division of Microbiology, Department of Basic Medical Sciences, Manipal Academy of Higher Education, Manipal, Udupi, Karnataka, 576104, India.
- Department of Pharmaceutical Biotechnology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Udupi, Karnataka, 576104, India. jesil.m@manipal.edu.
Förderung
- Manipal Academy of Higher Education, Manipal
Zitieren
APA
Ayswarya, K., Ibrahim, R., Veetilvalappil, V. V., Bhat, N. B., & Aranjani, J. M. (2026). Virulence arsenal of Acinetobacter baumannii: mechanisms driving persistence and resistance. Archives of Microbiology, 208(4). https://doi.org/10.1007/s00203-025-04668-7
Vancouver
Ayswarya K, Ibrahim R, Veetilvalappil VV, Bhat NB, Aranjani JM. Virulence arsenal of Acinetobacter baumannii: mechanisms driving persistence and resistance. Archives of Microbiology. 2026;208(4). doi:10.1007/s00203-025-04668-7
BibTeX
@article{Ayswarya2026,
author = {Ayswarya, K and Ibrahim, Rafwana and Veetilvalappil, Vimal V and Bhat, Nishanth B and Aranjani, Jesil Mathew},
title = {Virulence arsenal of Acinetobacter baumannii: mechanisms driving persistence and resistance},
journal = {Archives of Microbiology},
year = {2026},
volume = {208},
number = {4},
doi = {10.1007/s00203-025-04668-7}
}
EUVIMED